Skip to main content

Market Overview

Amgen Shares Dip On Light 2021 Outlook, Paused Studies

Share:
  • Amgen, Inc (NASDAQ: AMGN) stock dipped despite its Q4 2020 earnings beat, as investors digested the company's lower than expected 2021 outlook and a lineup of its cancer therapy studies that has been paused.
  • The company also said it expects net selling prices for its drugs to fall by a rate in the mid-single digits this year, after a drop of 6% in 2020, and the COVID pandemic will continue to impact sales.
  • For 2021, Amgen forecast adjusted EPS earnings of $16.00 to $17.00 per share and revenue of $25.8 billion to $26.6 billion, higher than 3% Y/Y, but that would decelerate from 9% sales growth in 2020.
  • Sales of rheumatoid arthritis drug Enbrel fell 5% to $1.27 billion in Q4, and sales from newer migraine drug Aimovig totaled $104 million for the quarter. But sales of cholesterol fighter Repatha rose 27% to $253 million. Increased competition from cheaper generics and biosimilars hit sales of older drugs such as infection-fighter Neulasta, which saw sales fall 19% to $536 million.
  • Amgen also flagged three cancer therapy studies has been halted due to efficacy or safety issues, which include:
  • AMG 673, a half-life extended BiTE molecule targeting CD33, has been paused while the company is gathering further information on the program through the progression of AMG 330.
  • AMG 596, a BiTE molecule targeting EGFR variant III for glioblastoma, has been stopped citing portfolio reprioritization.
  • Phase 1 development of the oral MCL-1 inhibitor AMG 397 was paused, with the focus shifting to the intravenous MCL-1 inhibitor AMG 176, currently in Phase 1 for hematologic malignancies.
  • AMGN shares are down 2.05% at $235.55 in thepre-market session on the last check Wednesday.
 

Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: Cancer TherapiesBiotech Earnings News Guidance Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com